You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 17, 2025

Margetuximab-cmkb - Biologic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


Summary for margetuximab-cmkb
Tradenames:1
High Confidence Patents:0
Applicants:1
BLAs:1
Suppliers: see list1
Pharmacology for margetuximab-cmkb
Mechanism of ActionHER2/Neu/cerbB2 Antagonists
Established Pharmacologic ClassHER2/neu Receptor Antagonist
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for margetuximab-cmkb Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for margetuximab-cmkb Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for margetuximab-cmkb Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Margetuximab-cmkb (MARGENZA)

Introduction

Margetuximab-cmkb, marketed as MARGENZA, is a significant addition to the treatment arsenal for metastatic HER2-positive breast cancer. Approved by the FDA in December 2020, this biologic drug has been making waves in the oncology market. Here, we delve into the market dynamics and financial trajectory of margetuximab-cmkb.

Approval and Clinical Significance

MARGENZA was approved for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. The approval was based on the pivotal Phase 3 SOPHIA trial, which demonstrated a statistically significant improvement in progression-free survival (PFS) compared to trastuzumab plus chemotherapy[1][4].

Market Need and Competition

The market for HER2-positive breast cancer treatments is highly competitive, with established drugs like trastuzumab and pertuzumab. However, the need for effective treatments that can address resistance and provide better outcomes remains high. MARGENZA fills this gap by offering an alternative with improved efficacy in patients who have failed previous anti-HER2 therapies.

Clinical Trial Outcomes

The SOPHIA trial showed that margetuximab-cmkb plus chemotherapy resulted in a median PFS of 5.8 months compared to 4.9 months for trastuzumab plus chemotherapy. The objective response rate (ORR) was 22% for margetuximab-cmkb versus 16% for trastuzumab. These outcomes underscore the clinical benefit of MARGENZA in a challenging patient population[1][4].

Safety Profile

The safety profile of MARGENZA is consistent with other anti-HER2 therapies. Common adverse reactions include fatigue, nausea, diarrhea, and infusion-related reactions. The drug also carries a Boxed Warning for left ventricular dysfunction and embryo-fetal toxicity[1].

Commercial Launch and Partnerships

MARGENZA was launched in the U.S. in March 2021, marking a significant milestone for MacroGenics, the drug's developer. The commercial success of MARGENZA is crucial for MacroGenics, given its position as the first approved product from the company's pipeline[2][3].

Financial Impact

The approval and launch of MARGENZA have had a positive impact on MacroGenics' financial trajectory. The company has generated significant revenue from the drug's sales and has also benefited from non-dilutive funding through partnerships and royalty monetization efforts. For instance, MacroGenics secured $265 million in non-dilutive funding in 2022 and early 2023, extending its cash runway through 2025[3].

Market Acceptance and Uptake

The market acceptance of MARGENZA has been favorable, driven by its clinical efficacy and the unmet need in the HER2-positive breast cancer market. Healthcare providers and patients have shown interest in this new treatment option, which has contributed to its growing market share.

Future Development and Combination Therapies

Margetuximab-cmkb is being evaluated in combination with other therapies, such as checkpoint inhibitors and antibody-drug conjugates, in various clinical trials. For example, the MAHOGANY trial is investigating margetuximab in combination with checkpoint blockade for HER2-positive gastroesophageal cancer. These ongoing and planned trials could further expand the drug's indications and enhance its market potential[2].

Regulatory Environment

The regulatory environment has been supportive of MARGENZA, with the FDA granting fast-track designation and approving the drug based on robust clinical data. This favorable regulatory landscape has facilitated the drug's rapid entry into the market and its ongoing development in other indications[1].

Challenges and Risks

Despite the positive trajectory, MacroGenics faces several challenges, including competition from established players, the need for continuous clinical validation, and the uncertainties associated with the broader economic and geopolitical environment. The company must navigate these risks while maintaining its focus on advancing its pipeline and commercializing its products[2][3].

Financial Projections and Milestones

MacroGenics is eligible to receive significant milestone and royalty payments related to the commercialization of MARGENZA and other products originating from its pipeline. The company's financial projections are optimistic, with a focus on sustaining growth through innovative product development and strategic partnerships[3].

Key Takeaways

  • Approval and Clinical Significance: MARGENZA was approved for metastatic HER2-positive breast cancer based on the SOPHIA trial, showing improved PFS and ORR.
  • Market Need and Competition: The drug addresses an unmet need in a competitive market, offering an alternative to trastuzumab.
  • Commercial Launch and Partnerships: Launched in March 2021, with significant revenue and non-dilutive funding.
  • Financial Impact: Positive impact on MacroGenics' financials, extending cash runway through 2025.
  • Future Development: Ongoing and planned trials in combination therapies to expand indications.

FAQs

What is margetuximab-cmkb (MARGENZA) used for?

MARGENZA is used for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.

What were the key findings of the SOPHIA trial?

The SOPHIA trial showed that margetuximab-cmkb plus chemotherapy resulted in a median PFS of 5.8 months compared to 4.9 months for trastuzumab plus chemotherapy, with an ORR of 22% versus 16% for trastuzumab[1].

What are the common adverse reactions associated with MARGENZA?

Common adverse reactions include fatigue, nausea, diarrhea, vomiting, and infusion-related reactions. The drug also carries a Boxed Warning for left ventricular dysfunction and embryo-fetal toxicity[1].

How has the commercial launch of MARGENZA impacted MacroGenics financially?

The launch of MARGENZA has generated significant revenue and non-dilutive funding, extending MacroGenics' cash runway through 2025[3].

What are the future development plans for margetuximab-cmkb?

Margetuximab-cmkb is being evaluated in combination with other therapies in various clinical trials, including the MAHOGANY trial for HER2-positive gastroesophageal cancer[2].

What regulatory designations has MARGENZA received?

MARGENZA received fast-track designation from the FDA, facilitating its rapid approval and development[1].

Sources

  1. FDA: FDA approves margetuximab for metastatic HER2-positive breast cancer.
  2. MacroGenics, Inc.: Annual Reports.
  3. MacroGenics, Inc.: ANNUAL REPORT 2022.
  4. VA.gov: Margetuximab-cmkb (Margenza) National Drug Monograph.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.